Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tragrisso

- PMLiVE

Santhera’s Raxone turned down for rare eye condition

EMA concerned about drug's ability to improve eyesight

- PMLiVE

EMA recommends suspension of Merck’s Tredaptive

Pharma company had already anticipated decision by withdrawing product worldwide

- PMLiVE

AstraZeneca removes R&D and commercial heads

Pascal Soriot's leadership shake-up will see Martin Mackay and Tony Zook leave

EMA launches eSubmission web tool

Will accept eCTD applications from January 15

- PMLiVE

EMA starts probe into MSD’s Tredaptive

Will investigate cholesterol drug's safety and efficacy after poor phase III results

- PMLiVE

EMA to focus on efficiency, transparency and new legislation in 2013

Regulator also plans significant staff reorganisation

Novartis building

Novartis’ Exjade gets EU approval for thalassaemia

First oral treatment for condition characterised by red blood cell problems and anaemia

- PMLiVE

AstraZeneca wins stay on Crestor generics in US

Appeals court upholds earlier ruling to validate patent until 2016

- PMLiVE

AstraZeneca’s fostamatinib fails to match Humira in RA

Inferiority to Abbott’s drug dents commercial prospects

- PMLiVE

EMA: move to greater clinical trial transparency ‘irreversible’

New Europe data rules could be ready by 2014

- PMLiVE

AstraZeneca antitrust fine upheld by European Court of Justice

Lessons for pharma as landmark ruling stands

- PMLiVE

EMA publishes drug shortages plan

Globalisation of manufacturing among key issues to address

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links